Artiva Biotherapeutics (ARTV) and The Competition Critical Review

Artiva Biotherapeutics (NASDAQ:ARTV) is one of 616 public companies in the “MED – BIOMED/GENE” industry, but how does it compare to its peers? We will compare Artiva Biotherapeutics to related businesses based on the strength of its analyst recommendations, profitability, earnings, risk, dividends, valuation and institutional ownership.

Valuation & Earnings

This table compares Artiva Biotherapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Artiva Biotherapeutics	$250,000.00	-$65.37 million	-1.60
Artiva Biotherapeutics Competitors	$962.33 million	-$40.42 million	8.31

Artiva Biotherapeutics’ peers have higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Artiva Biotherapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1	0	4	1	2.83
Artiva Biotherapeutics Competitors	7309	12684	38728	1236	2.57

Artiva Biotherapeutics currently has a consensus price target of $19.00, suggesting a potential upside of 358.94%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 60.07%. Given Artiva Biotherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than its peers.

Profitability

This table compares Artiva Biotherapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-49.99%	-44.05%
Artiva Biotherapeutics Competitors	-824.71%	-116.12%	-28.93%

Volatility and Risk

Artiva Biotherapeutics has a beta of 2.92, meaning that its share price is 192% more volatile than the S&P 500. Comparatively, Artiva Biotherapeutics’ peers have a beta of 1.02, meaning that their average share price is 2% more volatile than the S&P 500.

Institutional & Insider Ownership

51.3% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 13.3% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Artiva Biotherapeutics beats its peers on 8 of the 13 factors compared.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.